A Study of PLH-2301 in Subjects With Sarcopenia

Summary

This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of PLH-2301 in subjects with sarcopenia. Eligible subjects aged 65 years and older will be randomized to receive placebo or one of three dose levels of PLH-2301 once daily for 12 weeks. The primary objective is to assess the effect of PLH-2301 on physical function compared with placebo.

Timeline

Start

2026-05-08

Primary completion

2027-06-30

Completion

2027-06-30

Drugs

Indications